<?xml version="1.0" ?>
<!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd">

<pmc-articleset><article article-type="research-article" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">
<!--The publisher of this article does not allow downloading of the full text in XML form.-->
<front>
<journal-meta>
<journal-id journal-id-type="nlm-ta">Brain</journal-id>
<journal-id journal-id-type="iso-abbrev">Brain</journal-id>
<journal-id journal-id-type="publisher-id">brainj</journal-id>
<journal-title-group>
<journal-title>Brain</journal-title>
</journal-title-group>
<issn pub-type="ppub">0006-8950</issn>
<issn pub-type="epub">1460-2156</issn>
<publisher>
<publisher-name>Oxford University Press</publisher-name>
</publisher>
</journal-meta>
<article-meta>
<article-id pub-id-type="pmid">28137726</article-id>
<article-id pub-id-type="pmc">5837342</article-id>
<article-id pub-id-type="doi">10.1093/brain/aww357</article-id>
<article-id pub-id-type="publisher-id">aww357</article-id>
<article-categories>
<subj-group subj-group-type="heading">
<subject>Original Articles</subject>
</subj-group>
</article-categories>
<title-group>
<article-title>Molecular analyses of neurogenic defects in a human pluripotent stem cell model of fragile X syndrome</article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name>
<surname>Boland</surname>
<given-names>Michael J.</given-names>
</name>
<xref ref-type="aff" rid="aww357-AFF1">1</xref>
<xref ref-type="aff" rid="aww357-AFF2">2</xref>
<xref ref-type="corresp" rid="aww357-COR1"></xref>
<xref ref-type="author-notes" rid="aww357-FN1"></xref>
<xref ref-type="author-notes" rid="aww357-FN2"></xref>
<!--<email>mb4129@columbia.edu</email>-->
</contrib>
<contrib contrib-type="author">
<name>
<surname>Nazor</surname>
<given-names>Kristopher L.</given-names>
</name>
<xref ref-type="aff" rid="aww357-AFF1">1</xref>
<xref ref-type="aff" rid="aww357-AFF2">2</xref>
<xref ref-type="author-notes" rid="aww357-FN3"></xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Tran</surname>
<given-names>Ha T.</given-names>
</name>
<xref ref-type="aff" rid="aww357-AFF1">1</xref>
<xref ref-type="aff" rid="aww357-AFF2">2</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Szücs</surname>
<given-names>Attila</given-names>
</name>
<xref ref-type="aff" rid="aww357-AFF3">3</xref>
<xref ref-type="aff" rid="aww357-AFF4">4</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Lynch</surname>
<given-names>Candace L.</given-names>
</name>
<xref ref-type="aff" rid="aww357-AFF1">1</xref>
<xref ref-type="aff" rid="aww357-AFF2">2</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Paredes</surname>
<given-names>Ryder</given-names>
</name>
<xref ref-type="aff" rid="aww357-AFF5">5</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Tassone</surname>
<given-names>Flora</given-names>
</name>
<xref ref-type="aff" rid="aww357-AFF6">6</xref>
<xref ref-type="aff" rid="aww357-AFF7">7</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Sanna</surname>
<given-names>Pietro Paolo</given-names>
</name>
<xref ref-type="aff" rid="aww357-AFF8">8</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Hagerman</surname>
<given-names>Randi J.</given-names>
</name>
<xref ref-type="aff" rid="aww357-AFF7">7</xref>
<xref ref-type="aff" rid="aww357-AFF9">9</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Loring</surname>
<given-names>Jeanne F.</given-names>
</name>
<xref ref-type="aff" rid="aww357-AFF1">1</xref>
<xref ref-type="aff" rid="aww357-AFF2">2</xref>
<xref ref-type="corresp" rid="aww357-COR2"></xref>
<!--<email>jloring@scripps.edu</email>-->
</contrib>
</contrib-group>
<aff id="aww357-AFF1"><label>1</label>1 Department of Chemical Physiology, The Scripps Research Institute, La Jolla, CA, USA</aff>
<aff id="aww357-AFF2"><label>2</label>2 Center for Regenerative Medicine, The Scripps Research Institute, La Jolla, CA, USA</aff>
<aff id="aww357-AFF3"><label>3</label>3 BioCircuits Institute, University of California San Diego, La Jolla, CA, USA</aff>
<aff id="aww357-AFF4"><label>4</label>4 MTA-ELTE NAP-B Neuronal Cell Biology Group, Eötvös Lóránd University, Budapest, Hungary</aff>
<aff id="aww357-AFF5"><label>5</label>5 CIRM Bridges to Stem Cells Program, California State University Channel Islands, Camarillo, CA, USA</aff>
<aff id="aww357-AFF6"><label>6</label>6 Department of Biochemistry and Molecular Medicine, University of California Davis, Sacramento, CA, USA</aff>
<aff id="aww357-AFF7"><label>7</label>7 MIND Institute, University of California Davis, Sacramento, CA, USA</aff>
<aff id="aww357-AFF8"><label>8</label>8 Department of Molecular and Cellular Neuroscience, The Scripps Research Institute, La Jolla, CA, USA</aff>
<aff id="aww357-AFF9"><label>9</label>9 Department of Pediatrics, University of California Davis Medical Center, Sacramento, CA, USA</aff>
<author-notes>
<corresp id="aww357-COR2">Correspondence to: Jeanne Loring, Ph.D. Professor, Department of Chemical Physiology, Director, Center for Regenerative Medicine, The Scripps Research Institute, SP3030-3020 10550 North Torrey Pines Road, La Jolla, CA. 92037 USA E-mail: <email>jloring@scripps.edu</email></corresp>
<corresp id="aww357-COR1">Correspondence may also be addressed to: Michael Boland, Ph.D. Assistant Professor, Department of Neurology, Director, Cellular Models of Disease, Institute for Genomic Medicine, Columbia University, 630 W 168th St, P&amp;S 11-401A, New York, NY. 10032 USA E-mail: <email>mb4129@columbia.edu</email></corresp>
<fn id="aww357-FN1">
<p>*These authors contributed equally to this work.</p>
</fn>
<fn id="aww357-FN2">
<p>
<sup>#</sup>Present address: Institute for Genomic Medicine and Department of Neurology, College of Physicians and Surgeons, Columbia University, New York, NY, USA</p>
</fn>
<fn id="aww357-FN3">
<p>
<sup>†</sup>Present address: MYi Diagnostics and Discovery, San Diego, CA, USA</p>
</fn>
</author-notes>
<pub-date pub-type="ppub">
<month>3</month>
<year>2017</year>
</pub-date>
<pub-date iso-8601-date="2017-01-29" pub-type="epub">
<day>29</day>
<month>1</month>
<year>2017</year>
</pub-date>
<pub-date pub-type="pmc-release">
<day>01</day>
<month>3</month>
<year>2018</year>
</pub-date>
<!-- PMC Release delay is 12 months and
						0 days and was based on the <pub-date
						pub-type="ppub"/>. -->
<volume>140</volume>
<issue>3</issue>
<fpage>582</fpage>
<lpage>598</lpage>
<history>
<date date-type="received">
<day>5</day>
<month>7</month>
<year>2016</year>
</date>
<date date-type="rev-recd">
<day>30</day>
<month>11</month>
<year>2016</year>
</date>
<date date-type="accepted">
<day>3</day>
<month>12</month>
<year>2016</year>
</date>
</history>
<permissions>
<copyright-statement>© The Author (2017). Published by Oxford University Press on behalf of the Guarantors of Brain. All rights reserved. For Permissions, please email: journals.permissions@oup.com</copyright-statement>
<copyright-year>2017</copyright-year>
</permissions>
<self-uri xlink:href="aww357.pdf"></self-uri>
<abstract abstract-type="teaser">
<p>Fragile X Syndrome (FXS) often also presents with autism spectrum disorder (ASD). Boland <italic>et al</italic>. reveal consistent disease-associated phenotypes during neuronal differentiation of induced pluripotent stem cells from multiple patients diagnosed with FXS. FMR1- cells showed altered expression and epigenetic regulation of genes associated with ASD, suggesting common disease mechanisms.</p>
</abstract>
<abstract>
<title>Abstract</title>
<p>New research suggests that common pathways are altered in many neurodevelopmental disorders including autism spectrum disorder; however, little is known about early molecular events that contribute to the pathology of these diseases. The study of monogenic, neurodevelopmental disorders with a high incidence of autistic behaviours, such as fragile X syndrome, has the potential to identify genes and pathways that are dysregulated in autism spectrum disorder as well as fragile X syndrome. <italic>In vitro</italic> generation of human disease-relevant cell types provides the ability to investigate aspects of disease that are impossible to study in patients or animal models. Differentiation of human pluripotent stem cells recapitulates development of the neocortex, an area affected in both fragile X syndrome and autism spectrum disorder. We have generated induced human pluripotent stem cells from several individuals clinically diagnosed with fragile X syndrome and autism spectrum disorder. When differentiated to dorsal forebrain cell fates, our fragile X syndrome human pluripotent stem cell lines exhibited reproducible aberrant neurogenic phenotypes. Using global gene expression and DNA methylation profiling, we have analysed the early stages of neurogenesis in fragile X syndrome human pluripotent stem cells. We discovered aberrant DNA methylation patterns at specific genomic regions in fragile X syndrome cells, and identified dysregulated gene- and network-level correlates of fragile X syndrome that are associated with developmental signalling, cell migration, and neuronal maturation. Integration of our gene expression and epigenetic analysis identified altered epigenetic-mediated transcriptional regulation of a distinct set of genes in fragile X syndrome. These fragile X syndrome-aberrant networks are significantly enriched for genes associated with autism spectrum disorder, giving support to the idea that underlying similarities exist among these neurodevelopmental diseases.</p>
</abstract>
<kwd-group kwd-group-type="keywords">
<kwd>autism spectrum disorder</kwd>
<kwd>fragile X syndrome</kwd>
<kwd>neurogenesis</kwd>
<kwd>brain development</kwd>
<kwd>stem cells</kwd>
</kwd-group>
<funding-group>
<award-group award-type="grant">
<funding-source>
<named-content content-type="funder-name">National Institutes of Health</named-content>
<named-content content-type="funder-identifier">10.13039/100000002</named-content>
</funding-source>
</award-group>
<award-group award-type="grant">
<funding-source>
<named-content content-type="funder-name">National Institute on Drug Abuse</named-content>
<named-content content-type="funder-identifier">10.13039/100000026</named-content>
</funding-source>
<award-id>R21DA032975-01</award-id>
</award-group>
<award-group award-type="grant">
<funding-source>
<named-content content-type="funder-name">National Institute of Mental Health</named-content>
<named-content content-type="funder-identifier">10.13039/100000025</named-content>
</funding-source>
<award-id>R33MH087925-04</award-id>
</award-group>
<award-group award-type="grant">
<funding-source>
<named-content content-type="funder-name">CIRM</named-content>
</funding-source>
<award-id>CL1-00502, TR01250, RM1-01717, and TR3-05603</award-id>
</award-group>
<award-group award-type="grant">
<funding-source>
<named-content content-type="funder-name">Hungarian Brain Research Program</named-content>
</funding-source>
<award-id>KTIA_NAP_13-2014-0018</award-id>
</award-group>
<award-group award-type="grant">
<funding-source>
<named-content content-type="funder-name">NICHD</named-content>
</funding-source>
<award-id>HD02274</award-id>
</award-group>
</funding-group>
<counts>
<page-count count="17"></page-count>
</counts>
</article-meta>
</front>
</article>
</pmc-articleset>